anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled antibody, by immunizing an animal immunologically tolerant to normal human cell with human tumor cell, etc., fusing the antibody-producing cell with myeloma cell of said animal, and selecting and culturing the obtained hybridoma. CONSTITUTION:An animal which is made to be immunologically tolerant to normal human cell or normal human tissue or their cell wall component, is immunized with human tumor cell, tumor tissue or their cell wall component. The antibody-producing cell of said immunized animal is fused with myeloma cell to obtain hybridoma. A hybridoma capable of producing a monoclonal antibody reactive specifically and solely to said tumor cell or tumor tissue or their cell wall component is selected from the produced hybridoma. The selected hybridoma is cultured in a medium or converted to ascites in an animal to obtain a monoclonal antibody reactive specifically with said human tumore cell or tumor tissue or thier cell wall component. The antibody is useful for the diagnosis of tumor, etc.
The invention relates to a recombinant bacillus subtilis (B.S. -HA) for expressing highly pathogenic Avian Influenza (AIV) H5N1 hemagglutinin HA protein, belonging to the field of biotechnology and genetic engineering. The invention successfully constructs a highly pathogenic avian influenza hemagglutinin HA protein recombinant bacillus subtilis expression plasmid pHT43, and successfully transfers the recombinant bacillus subtilis expression plasmid into a bacillus subtilis WB800N strain (B.S) by electric shock. Western-blot verifies that the highly pathogenic avian influenza hemagglutinin HA protein can be successfully expressed in the recombinant bacillus subtilis. Oral immunization stimulates the body of a 10-day-old chick to produce an effective level of AIV-specific immune response. The recombinant bacillus subtilis (B.S. -HA) is expected to be developed into a genetic engineering oral vaccine for preventing highly pathogenic avian influenza.
Progressive cerebral infarction (PCI) is a common complication in patients with ischemic stroke that leads to poor prognosis. Blood pressure (BP) can indicate post-stroke hemodynamic changes which play a key role in the development of PCI. The authors aim to investigate the association between BP-derived hemodynamic parameters and PCI. Clinical data and BP recordings were collected from 80 patients with cerebral infarction, including 40 patients with PCI and 40 patients with non-progressive cerebral infarction (NPCI). Hemodynamic parameters were calculated from the BP recordings of the first 7 days after admission, including systolic and diastolic BP, mean arterial pressure, and pulse pressure (PP), with the mean values of each group calculated and compared between daytime and nighttime, and between different days. Hemodynamic parameters and circadian BP rhythm patterns  were compared between PCI and NPCI groups using t-test or non-parametric equivalent for continuous variables, Chi-squared test or Fisher's exact test for categorical variables, Cox proportional hazards regression analysis and binary logistic regression analysis for potential risk factors. In PCI and NPCI groups, significant decrease of daytime systolic BP appeared on the second and sixth days, respectively. Systolic BP and fibrinogen at admission, daytime systolic BP of the first day, nighttime systolic BP of the third day, PP, and the ratio of abnormal BP circadian rhythms were all higher in the PCI group. PCI and NPCI groups were significantly different in BP circadian rhythm pattern. PCI is associated with higher systolic BP, PP and more abnormal circadian rhythms of BP.
On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
Embodiments of this invention include methods for decreasing hypertension in mammals subjected to adverse cardiovascular fetal programming or a long-term adverse postnatal environment. Fetal programming can result from adverse intrauterine conditions, including growth retardation or undernutrition. Adverse postnatal environments include either hypocaloric or hypercaloric nutrition. Decreasing hypertension is such mammals can be accomplished by administering an agent that increases the effective amount of a growth hormone. Such agents can include a growth hormone, an agent that increases the effective concentration of a growth hormone in the mammal, or an agent that decreases inhibition of a growth hormone's effects. Such agents can be used either alone, or in combination with other anti-hypertensive agents.
TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
The purpose of this study is to identify host genetic factors that contribute to the development of Progressive Multifocal Leukoencephalopathy (PML) associated with JC virus. JC virus is one of many opportunistic infections that arise in AIDS patients. JC virus is widely distributed in the general population, with estimates of population exposure ranging from 30-80%. JC virus remains latent in the host, and in profoundly immunosuppressed patients, JC virus can cause PML, a fatal disease associated with neurotropic JC virus that lytically infects oligodendrocytes. In untreated AIDS populations, the frequency of PML has been estimated at roughly 5%. This study will identify host genetic factors that may contribute to the development of PML in the AIDS population.
Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is an immunomodulatory drug (a drug that affects the immune system) which alters the body's immune system and it may also interfere with the development of tiny blood vessels involved in tumor growth. Therefore, lenalidomide may reduce or prevent the growth of cancer cells. Lenalidomide has also been shown to restore the immune cells' ability to attack and kill tumor cells, an ability that may be inhibited by follicular lymphoma and other lymphomas. The combination of rituximab and lenalidomide may eliminate the cancer while restoring the immune system's ability to attack tumor cells.
1.5% Glycine Irrigation, USP should be administered only by transurethral instillation with appropriate urologic instrumentation. A disposable irrigation set should be used. The total volume of solution used for irrigation is solely at the discretion of the surgeon.

Height of container(s) above the operating table in excess of 60 cm (approx. 2 ft.) has been reported to increase intravascular absorption of the irrigating fluid.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution container permits. See PRECAUTIONS.
<P>PROBLEM TO BE SOLVED: To provide a highly immunogenic vaccine containing a modified group C meningococcal polysaccharide (GCMP) coupled to carrier molecules, furthermore, a highly immunogenic vaccine containing a conjugate with a modified polysaccharide derived from an OAc negative mutant.  <P>SOLUTION: An immunogenic conjugate comprising the modified C group meningococcal polysaccharide (GCMP) coupled to the carrier molecule is provided. The GCMP is modified to various degrees by O-deacetylation. The modified GCMP conjugate stimulates a strong immunogenic response. The antiserum produced by immunization with the conjugate is cross-reactive with the native polysaccharides. In addition, the antisera induce a class of antibodies having potent microbicidal activity.  <P>COPYRIGHT: (C)2008,JPO&INPIT
OBJECTIVE: Over recent years, there has been a growing interest in exploring the utility of seizure risk forecasting, particularly how it could improve quality of life for people living with epilepsy. This study reports on user experiences and perspectives of a seizure risk forecaster app, as well as the potential impact on mood and adjustment to epilepsy.
METHODS: Active app users were asked to complete a survey (baseline and 3-month follow-up) to assess perspectives on the forecast feature as well as mood and adjustment. Post-hoc, nine neutral forecast users (neither agreed nor disagreed it was useful) completed semi-structured interviews, to gain further insight into their perspectives of epilepsy management and seizure forecasting. Non-parametric statistical tests and inductive thematic analyses were used to analyse the quantitative and qualitative data, respectively.
RESULTS: Surveys were completed by 111 users. Responders consisted of "app users" (n = 58), and "app and forecast users" (n = 53). Of the "app and forecast users", 40 % believed the forecast was accurate enough to be useful in monitoring for seizure risk, and 60 % adopted it for purposes like scheduling activities and helping mental state. Feeling more in control was the most common response to both high and low risk forecasted states. In-depth interviews revealed five broad themes, of which 'frustrations with lack of direction' (regarding their current epilepsy management approach), 'benefits of increased self-knowledge' and 'current and anticipated usefulness of forecasting' were the most common.
SIGNIFICANCE: Preliminary results suggest that seizure risk forecasting can be a useful tool for people with epilepsy to make lifestyle changes, such as scheduling daily events, and experience greater feelings of control. These improvements may be attributed, at least partly, to the improvements in self-knowledge experienced through forecast use.
BACKGROUND: Open repair of thoracoabdominal aortic aneurysm (TAAA) was characterized by significant risk of postoperative mortality and morbidity. The aim of this study was to determine the perioperative predictors of early and long-term mortality in patients undergoing open repair of TAAA. Besides, the postoperative outcomes in patients with open repair of TAAA were described.
METHODS: This is a single-center retrospective study, and 146 patients with open repair of TAAA from January 4, 2011, to November 22, 2018 was involved. Categorical variables were analyzed by the Chi-square test or Fisher's exact test, and continuous variables were analyzed by the independent sample t-test and the WilCoxon rank-sum test. Multivariate Logistic regression and Cox regression were applied to identify the predictors of 30-day and long-term mortality, respectively. The Kaplan Meier curves were used to illustrate survival with the Log-rank test.
RESULTS: The 30-day mortality was 9.59% (n = 14). Older than 50 years, the intraoperative volume of red blood cell (RBC) and epinephrine use were independently associated with postoperative 30-day mortality in open repair of TAAA. Long-term mortality was 17.12% (n = 25) (median of 3.5 years (IQR = 2-5 years) of follow-up). Prior open thoracoabdominal aortic aneurysm (TAAA) repair, aortic cross-clamping (ACC) time, intraoperative volume of RBC and use of epinephrine were independently correlated with long-term mortality.
CONCLUSIONS: Identifying perioperative risk factors of early and long-term mortaliy is crucial for surgeons. Intraoperative volume of RBC and use of epinephrine were predictors of both early and long-term mortality. In addition, patients of advanced age, prior open repair of TAAA and prolonged ACC time should be paid more attention.
PURPOSE:To improve flowing out and an usability by preparing a surfactant composition by formulating an anionic surfactant, water and a polyhydric alcohol at a specific formulating proportion, and forming a transparent and highly viscous liquid crystal by adding a little water. CONSTITUTION:A surfactant composition containing three ingredients of an anionic surfactant, water and a polyhydric alcohol and having a composition in which the weight ratio of three ingredients is within the area surrounded by points alpha, beta, (b) and (d) as indicated by hatching in figure 1, is prepared. Concn. of the anionic surfactant is preferably ranged within 20-60wt.%, and sodium laurate, potassium palmitate, sodium myristate, etc., are concretely exemplified as the anionic surfactant. Concn. of the polyhydric alcohol is preferably ranged within 10-40wt.%, and as the polyhydric alcohol, a divalent alcohol such as propylene glycol and a trivalent alcohol such as glycerine are concretely exemplified. Moreover, the referable concn. of water is ranged within 10-60wt.%.
PURPOSE:To provide a percutaneously absorbable plaster excellent in adhesivity and not giving irritation to skins and also pain to the skins when peeled. CONSTITUTION:An self-adhesive layer comprising 100 pts.wt. of a self-adhesive agent, 10-40 pts.wt. of a medicinal substance (e.g. 17-beta-estradiol), if necessary, furthermore a tackifying resin and a percutaneous absorption-accelerating agent is laminated to one side of a support. The self-adhesive agent comprises 5-20 pts.wt. of a polyvinyl pyrrolidone having a mol.wt. of 1000000-5000000 and 100 pts.wt. of either of a silicone adhesive and an acrylic adhesive agent comprising the acrylic copolymer of one or more methacrylate compounds selected from dodecyl methacrylate and octyl methacrylate with one or more acrylate compounds selected from dodecyl acrylate and octyl acrylate. The medicinal substance is contained in the self-adhesive agent in a supersaturated state exceeding the solubility of the self-adhesive agent, and the supersaturated state can stably be maintained for a long period.
Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
The present invention provides a sustained-release creatine preparation, which comprises 30-95% of creatine compound in weight percent and 5-70% of sustained-release material in weight percent. The creatine sustained-release preparation is executed with sustained-release processing and causes that the creatine is released slowly and continuously in vivo. The absorption rate is increased. Furthermore the gastrointestinal tract reaction caused by the simultaneously releasing of large amount of creatine in the stomach is prevented. The liver-kidney burden increasing caused by the discharging of redundant creatine by liver metabolism and urine is prevented. Compared with the common creatine, the sustained-release creatine has better effect in the aspects of increasing explosive force, promoting the growth of muscle, etc.
An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
Systems and methods comprising a sensor for sensing a biological target and generating a signal and a simulator for using the signal and a model of the target to generate a therapeutic or diagnostic output are claimed. The sensor may be reconfigurable by the simulator. The system may also comprise a further sensor which senses food consumed by the biological target to generate a second signal that is used by the simulator, preferably in association with a regulatory condition for example a FDA guideline. Also claimed are systems with biosensors for DNA or RNA, peptides or proteins, antibody or antigen, vector, virus, lipid, fatty acid, inorganic or electrochemical substrates. The simulation models maybe for genomics, proteomics, computational chemistry, pharmacogenomics, computational biology, computational biophysics, cell behaviour, pharmacokinetics, metabolomics or transcriptomics. The system may have a neural network, fuzzy logic or similar means of programming.
Aggressive peripheral T-cell lymphomas account for 10 - 15% of all Non-Hodgkin's Lymphoma (NHL) and present with more adverse prognostic features than aggressive histology B-cell NHL . Correspondingly, they have an overall poorer prognosis than B-cell lymphomas, achieving lower complete response rates, freedom from progression and overall survival with conventional anthracycline-based CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. Fewer than 30% of patients are cured with therapy. New treatments that replicate the improved survivals with chemo-immunotherapy for B-cell lymphomas are needed. Alemtuzumab is a humanized murine antibody that binds to a ubiquitous lymphoid marker CD52 and is efficacious (as monotherapy) in related lymphoproliferative diseases. Combining alemtuzumab with CHOP chemotherapy may improve the response rates and outcomes of patients with this sub-type of NHL. The combination must be first tested in a dose escalation fashion to establish the dosage of the doublet because of the potential for overlapping or exaggerated toxicities.

This prospective, multi-center, open label Phase I-II study will enroll 22-84 patients with newly diagnosed previously untreated aggressive histology peripheral T-cell lymphomas. In the Phase I component, patients will be sequentially enrolled in cohorts of three patients and treated with increasing doses of alemtuzumab administered in combination with standard CHOP chemotherapy. When the maximal tolerated dose is determined, this dose and schedule will then be tested in up to 46 patients using a Simon two stage Phase II design.
The present invention relates to a nutritional product for cerebrovascular and cardiovascular health care, which is formed mainly by mixing ribose complex, L-arginine, L-tryptophan, natto extract, bacillus natto fermentation product, olive extract, natural plant extract, coenzyme Q10 and red yeast rice. The ribose complex includes D-ribose, palm oil and nicotinamide. The natto extract includes natto-kinase and maltodextrin. The bacillus natto fermentation product includes acacia gum, sucrose, water, L-ascorbyl palmitate and polysorbate. The olive extract includes maltodextrin and silicon dioxide. The natural plant extracts includes green coffee bean extract, green tea extract, turmeric extract, sour cherries, blueberries, cauliflower and kale. With the aforementioned composition, NAD+ can be effectively synthesized in the human body to activate the anti-aging mechanism and generate nitric oxide so as to achieve the purpose of expanding the cerebrovascular and cardiovascular system and facilitating blood circulation.
Cosmetic lasers are a well-established, popular modality for removal of unwanted hair, treatment of all types of vascular lesions, including hemangiomas, port wine stains, and a variety of telangiectases as well as facial rhytides reduction. The existing lasers are based on a wavelength that is specifically absorbed by the chromophore found in the target such as hair follicle, where the energy is converted to heat resulting in a thermal injury. However, the lasers for cosmetic treatments are not without limitations. A laser based long-term hair removal treatment is based on thermal destruction of the hair shaft and follicle using wavelengths that are specifically absorbed by the pigment melanin found in the hair follicle. The heating of hair follicle is done through heat dissipation from the hair shaft. One of the significant limitations of this approach is the fact that the epidermis through which the light energy must penetrate is rich in melanin and therefore absorbs a major portion of the energy, resulting in inadequate heating of the hair follicles. Similar problem exists when targeting other chromophores such as hemoglobin or water. The purpose of the study is an evaluation of safety and efficacy of a new laser based device.
Philips Healthcare has devised a new home full blood count (FBC) home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count). The system will also allow patients to record their temperature and symptoms. The Philips home telemonitoring system is called the Zodiac and consists of a telecommunications hub connected to a haematology analyser. The Hub connects to medical device software running on a remote server which controls the flow of information between the Hub and the clinician. This is designed to enable the patient to self test their full blood count in their home and transmit the data remotely to a clinician for review. In addition to testing their full blood count, the patients can input their temperature and any symptoms they have onto the device. The clinician will then be able to send appropriate instructions back to the patient. The Philips Zodiac system can also send a preprogrammed automated message based on the results of testing.